The relative risk of clinically relevant cholelithiasis among glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus, real-world study.

MLA

Gameil, Mohammed Ali, et al. “The Relative Risk of Clinically Relevant Cholelithiasis among Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus, Real-World Study.” Diabetology & Metabolic Syndrome, vol. 16, no. 1, Dec. 2024, pp. 1–10. EBSCOhost, https://doi.org/10.1186/s13098-024-01526-2.

APA

Gameil, M. A., Yousef, E. A. A. M., Marzouk, R. E., Emara, M. H., Abdelkader, A. H., & Salama, R. I. (2024). The relative risk of clinically relevant cholelithiasis among glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus, real-world study. Diabetology & Metabolic Syndrome, 16(1), 1–10. https://doi.org/10.1186/s13098-024-01526-2

Chicago

Gameil, Mohammed Ali, Elshahat Ali Ahmed Mohamed Yousef, Rehab Elsayed Marzouk, Mohamed H. Emara, Abeer H. Abdelkader, and Rasha Ibrahim Salama. 2024. “The Relative Risk of Clinically Relevant Cholelithiasis among Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus, Real-World Study.” Diabetology & Metabolic Syndrome 16 (1): 1–10. doi:10.1186/s13098-024-01526-2.